LONDON (Reuters) – Specialist medicine company BTG received a triple dose of good news on Monday as U.S. regulators approved two new treatments and a clinical trial of a novel lung device produced positive results. U.S. green lights for Vistogard and Lumi, for chemotherapy overdoses and tumors, and the success of PneumRx coils in severe emphysema may go some way to counter recent disappointment over sales of BTG’s varicose vein treatment Varithena. (Reporting by Ben Hirschler, editing by Louise Heavens)
Go here to read the rest:
BTG gets triple dose of good news on new products
